Literature DB >> 31392138

Long term results of the NRG/RTOG 9413: a key study but one of the most confusing study in prostate cancer radiotherapy!

Pascal Pommier1.   

Abstract

Entities:  

Year:  2019        PMID： 31392138      PMCID： PMC6642955          DOI： 10.21037/tau.2019.04.01

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  17 in total

1.  Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?

Authors:  Michael A Weller; Patrick A Kupelian; Chandana A Reddy; Kevin L Stephans; Rahul D Tendulkar
Journal:  Clin Genitourin Cancer       Date:  2014-12-31       Impact factor: 2.872

2.  Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

Authors:  Mack Roach; Michelle DeSilvio; Richard Valicenti; David Grignon; Sucha O Asbell; Colleen Lawton; Charles R Thomas; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

3.  Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.

Authors:  Steven J Feigenberg; Alexandra L Hanlon; Eric M Horwitz; Robert G Uzzo; Debra Eisenberg; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

4.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Authors:  M Roach; M DeSilvio; C Lawton; V Uhl; M Machtay; M J Seider; M Rotman; C Jones; S O Asbell; R K Valicenti; S Han; C R Thomas; W S Shipley
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

5.  Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.

Authors:  Colleen A Lawton; Kyoungwha Bae; Miljenko Pilepich; Gerald Hanks; William Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-19       Impact factor: 7.038

6.  RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

Authors:  Richard K Valicenti; Kathryn Winter; James D Cox; Howard M Sandler; Walter Bosch; Srinivasan Vijayakumar; Jeff Michalski; James Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-01       Impact factor: 7.038

7.  Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.

Authors:  Peter H Ahn; Ha Thanh Vu; Donald Lannin; Edward Obedian; Michael P DiGiovanna; Barbara Burtness; Bruce G Haffty
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

8.  Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.

Authors:  C Bourgier; S Kerns; S Gourgou; C Lemanski; M Gutowski; P Fenoglietto; G Romieu; N Crompton; J Lacombe; A Pèlegrin; M Ozsahin; B Rosenstein; D Azria
Journal:  Ann Oncol       Date:  2015-12-17       Impact factor: 32.976

Review 9.  Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.

Authors:  Matthew J Cecchini; Edward Yu; Kylea Potvin; David D'souza; Michael Lock
Journal:  Cureus       Date:  2015-10-25

10.  Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.

Authors:  G Sanguineti; S Agostinelli; F Foppiano; P Franzone; S Garelli; M Marcenaro; M Orsatti; V Vitale
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.